Table 1.
Study | Study drug | Subject characteristics | Effect on lipid panel | Effect on CHD | Attribution to changes in major plasma lipid levels |
---|---|---|---|---|---|
S418,19 | Simvastatin 20–40 mg | 4444 men and women age 35–70 with angina pectoris or previous MI and TC 213–310, TG ≤ 220 | Decreases TC, LDL by 25% and 35% respectively, increases HDL by 8% | Relative risk of MCE reduced by 34%, relative risk of coronary death and all-cause death is 0.58 (CI 0.46–0.73) and 0.70 (CI 0.58–0.85) respectively | Each additional 1% reduction in LDL reduces MCE risk by 1.7% (CI 1.0%–2.4%); each 1% reduction in TC decreases risk for MCE by 1.9% (1.0–2.8); each 1% reduction in HDL decreases risk by 0.8% (0.1–1.5), NS with TG |
BIP27 | Bezafibrate 400 mg per day | 3122 men and women age 45–74 with history of MI or angina; baseline TC 180–250, LDL ≤ 180, HDL ≤ 45, TG ≤ 300 | Divided into tertiles; tertile 1 includes subjects with HDL change of ≤3.4 mg/dL, tertile 2 includes subjects with HDL change between +3.41 to +8.02 mg/dL, and tertile 3 includes any subjects with HDL change ≥8.03 mg/dL | NS in cardiac mortality between the bezafibrate and placebo group; significant difference in cardiac mortality between tertile 2 and 3 versus the other subjects | Risk of cardiac mortality decreases by 27% for every 5 mg/dL increase in HDL |
VA-HIT28,54 | Gemfibrozil 1200 mg per day | 2531 men, less than 74 years old with history of CHD; baseline: low HDL (mean 32 mg/dL), low LDL (mean 111 mg/dL); mean TC 175 mg/dL, and mean TG 162 mg/dL | Compared to placebo, gemfibrozil decreases TC, TG by 4%, 31% respectively, increases HDL by 6%, NS LDL in one year | Relative risk reduction of CHD event is 22% (7–35); 24% reduction in combined death from CHD, nonfatal MI, and stroke; NS in all-cause death | Incidence of MI or CHD death is inversely related to HDL, NS with TG and LDL |
Helsinki Heart Study21,55 | Gemfibrozil 600 mg twice a day | 4081 men, 40–55 years old, dyslipidemic asymptomatic, non-HDL > 200 mg/dL | Decreases TC, TG, LDL by 11%, 43%, 10% respectively, increases HDL by about 11% from baseline | Decreases incidence of CHD such as MI and cardiac death by 34% (CI 8.2%–52.6%), no difference in total death | Changes in HDL and LDL are associated with CHD incidence in treatment group; NS TG; proportional hazards model estimates that changes of +8% in HDL, −7% in LDL would reduce CHD incidence by 23%, 15% respectively |
LRC-CPPT20 | Cholestyramine 24 g/day | 3806 men; Asymptomatic middle age men with primary hypercholesterolemia (Type II) | Decreases TC and LDL by 13.4% and 20.3% respectively compared to baseline, 8.5% and 12.6% respectively compared to placebo; treatment group have about 3% higher HDL than placebo | Decreases relative risk of CHD death and nonfatal MI by 19%, no difference in all-cause death | Majority of the reduction in CHD is attributed to decreases in TC and LDL; small increase in HDL accounts for 2% relative risk reduction in CHD |
Abbreviations: LDL, low-density lipoprotein, all units in mg/dL; HDL, high-density lipoprotein, all units in mg/dL; TC, total cholesterol, all units in mg/dL; TG, triglyceride, all units in mg/dL; CHD, coronary heart disease; MI, myocardial infarction; MCE, major coronary event; NS, no statistical difference.